GILD241108P80000
- 0.14
- -0.01-6.67%
Gilead Sciences Newsroom
Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
Gilead Science to Report Q3 Earnings: What's in the Cards?
Gilead Sciences Hits 8-1/2-year High
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $105
Jefferies Remains a Buy on Gilead Sciences (GILD)
US Equity Investors to Look Out for Presidential Election Results, Fed Rate Cut, Quarterly Earnings This Week
Nvidia, Apple, Sherwin-Williams, DJT, Viking Therapeutics, Talen Energy, and More Stock Market Movers
Earnings Week Ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and More
Express News | JEFFERIES: Raised Gilead's target price from $95 to $105.
Express News | Gilead : Jefferies Raises Target Price to $105 From $95
Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week
Earnings Preview: GILD to Report Financial Results Post-market on November 06
$Gilead Sciences(GILD.US)$ is scheduled to release its financial results post-market on November 06 ET. Earnings PreviewAnalysts estimate $Gilead Sciences(GILD.US)$ to post revenue of USD7.00B for 202
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Retail Resilience: Kontoor Brands Rallies to an All-time High After Better-than-expected Earnings
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
NACD Announces 2024 Diversity, Equity, and Inclusion Award Winners
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $75 Price Target
IDEAYA Reports Phase 1 Expansion Data for IDE397